This protocol continues implementation of a laboratory model to evaluate medications potentially useful in the treatment of cocaine abuse, investigating problems relevant to understanding and reducing uncontrolled cocaine use. Psychiatric comorbidities are pervasive in the cocaine-dependent population, and are significant in the population seen in community treatment centers. However, these comorbidities are rarely addressed in either clinical trials or laboratory settings. While it has been hypothesized that treatment for cocaine dependence could be improved by targeting cocaine users with specific psychiatric comorbidities, this has not been systematically evaluated. We will examine the relationship between psychiatric comorbidity and potential medications for cocaine dependence using two approaches. First, we will compare the subjective and reinforcing effects of cocaine under controlled laboratory conditions, in groups of abstinent cocaine abusers with Major Depressive Disorders (MDD), Attention Deficit/Hyperactivity Disorder (ADHD) or no psychiatric comorbidity. If cocaine use in individuals with comorbid disorders is related to their comorbid. disorder, then the behavioral effects of cocaine should vary across the groups being studied. Second, we will compare responses to cocaine under three separate conditions: maintenance on 1) gabapentin, 2) venlafaxine, and 3) the combination of the two medications. The laboratory, setting of the current proposal offers a unique opportunity to test the hypothesis that individuals with comorbid MDD or ADHD respond differently to cocaine than those without a comorbid psychiatric disorder, and that treating the MDD or ADHD alone will not sufficiently reduce the response to cocaine. Treating the comorbid disorder or decreasing the behavioral effects of cocaine will be necessary but not sufficient pharmacotherapy for individuals with comorbid disorders. A combination of the gabapentin for cocaine and venlafaxine for depressive symptoms will have a synergistic effect in these individuals. The laboratory is an ideal setting in which to carry out this research, allowing us to carefully monitor participants and collect maximal data with the fewest number of participants. The proposed research offers a unique opportunity to evaluate medications in cocaine-dependent individuals with MDD, ADHD or no comorbid disorder, and will provide important information about differential responses of these groups to cocaine and to gabapentin and venlafaxine, alone and in combination.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA006234-12
Application #
6647060
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Majewska, Maria D
Project Start
1990-01-01
Project End
2007-05-31
Budget Start
2003-06-01
Budget End
2004-05-31
Support Year
12
Fiscal Year
2003
Total Cost
$579,586
Indirect Cost
Name
Columbia University (N.Y.)
Department
Psychiatry
Type
Schools of Medicine
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Kalapatapu, Raj K; Bedi, Gillinder; Haney, Margaret et al. (2012) Substance use after participation in laboratory studies involving smoked cocaine self-administration. Drug Alcohol Depend 120:162-7
Kalapatapu, Raj K; Bedi, Gillinder; Haney, Margaret et al. (2012) The subjective effects of cocaine: relationship to years of cocaine use and current age. Am J Drug Alcohol Abuse 38:530-4
Kalapatapu, Raj K; Vadhan, Nehal P; Rubin, Eric et al. (2011) A pilot study of neurocognitive function in older and younger cocaine abusers and controls. Am J Addict 20:228-39
Haney, Margaret; Rubin, Eric; Foltin, Richard W (2011) Aripiprazole maintenance increases smoked cocaine self-administration in humans. Psychopharmacology (Berl) 216:379-87
Vosburg, Suzanne K; Hart, Carl L; Haney, Margaret et al. (2010) Modafinil does not serve as a reinforcer in cocaine abusers. Drug Alcohol Depend 106:233-6
Hart, Carl L; Haney, Margaret; Vosburg, Suzanne K et al. (2008) Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 33:761-8
Comer, S D; Ashworth, J B; Foltin, R W et al. (2008) The role of human drug self-administration procedures in the development of medications. Drug Alcohol Depend 96:1-15
Hart, Carl L; Haney, Margaret; Vosburg, Suzanne K et al. (2007) Gabapentin does not reduce smoked cocaine self-administration: employment of a novel self-administration procedure. Behav Pharmacol 18:71-5
Zernig, Gerald; Ahmed, Serge H; Cardinal, Rudolf N et al. (2007) Explaining the escalation of drug use in substance dependence: models and appropriate animal laboratory tests. Pharmacology 80:65-119
Hart, Carl L; Haney, Margaret; Collins, Eric D et al. (2007) Smoked cocaine self-administration by humans is not reduced by large gabapentin maintenance doses. Drug Alcohol Depend 86:274-7

Showing the most recent 10 out of 31 publications